Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-10-30
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 838
- Registration Number
- NCT02278341
- Locations
- 🇵🇱
Site PL48002, Katowice, Poland
🇭🇷Site HR38509, Zagreb, Grad Zagreb, Croatia
🇭🇷Site HR38505, Karlovac, Croatia
A Study to Evaluate the Effects of Multiple Doses of FG-4592 on the Exposure, Safety and Tolerability and Effect of Warfarin in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-09-30
- Last Posted Date
- 2014-09-30
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 22
- Registration Number
- NCT02252731
- Locations
- 🇩🇪
Parexel International GmbH, Berlin, Germany
A Study to Assess the Safety, Tolerability, and Effects in and on the Body of Healthy Young and Elderly Male and Female Subjects of Ascending Multiple Oral Doses of ASP3652
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-09-18
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 101
- Registration Number
- NCT02243657
- Locations
- 🇳🇱
PRA International, Groningen, Netherlands
A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer
- First Posted Date
- 2014-08-26
- Last Posted Date
- 2017-06-27
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 12
- Registration Number
- NCT02225093
- Locations
- 🇲🇩
Arensia, Chisinau, Moldova, Republic of
A Study to Assess the Effects of Single Ascending Doses (SAD) of ASP8477, the Effect That Food Has on the Drug, and the Interaction Between ASP8477 and Omeprazole in Healthy Postmenopausal Females and Healthy Young Vasectomized Males
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 72
- Registration Number
- NCT02220777
- Locations
- 🇧🇪
SGS Belgium N.V., Antwerp, Belgium
🇫🇷SGS Aster, Paris, France
A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
- First Posted Date
- 2014-08-18
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 148
- Registration Number
- NCT02218372
- Locations
- 🇩🇪
Site DE49006, Freiburg, Germany
🇫🇷Site FR33002, La Tronche, France
🇺🇸Site US10014, Toledo, Ohio, United States
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 55
- Registration Number
- NCT02218099
- Locations
- 🇧🇬
Site: 35901, Sofia, Bulgaria
🇲🇩Site: 37301, Chisinau, Moldova, Republic of
🇷🇴Site: 40001, Bucharest, Romania
A Study to Assess the Interaction Between ASP1707 and Itraconazole in Healthy Female Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2014-07-03
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 14
- Registration Number
- NCT02175407
- Locations
- 🇩🇪
PAREXEL International GmbH, Berlin, Germany
Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-06-23
- Last Posted Date
- 2014-08-29
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 20
- Registration Number
- NCT02169713
- Locations
- 🇩🇪
Parexel International GmbH, Berlin, Germany
A Study to Evaluate the Dose-proportionality and Effects of FG-4592 in Healthy Young and Elderly Male and Female Subjects
- First Posted Date
- 2014-06-12
- Last Posted Date
- 2014-06-12
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 48
- Registration Number
- NCT02161796
- Locations
- 🇩🇪
Parexel International GmbH, Berlin, Germany
© Copyright 2024. All Rights Reserved by MedPath